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Abstract
Background: Interleukin-17A (IL-17A) is the founding member of a novel family of inflammatory
cytokines that plays a critical role in the pathogenesis of many autoimmune diseases, including multiple
sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). IL-17A signals
through its receptor, IL-17RA, which is expressed in many peripheral tissues; however, expression of IL-
17RA in the central nervous system (CNS) and its role in CNS inflammation are not well understood.
Methods: EAE was induced in C57Bl/6 mice by immunization with myelin oligodendroglial glycoprotein.
IL-17RA expression in the CNS was compared between control and EAE mice using RT-PCR, in situ
hybridization, and immunohistochemistry. Cell-type specific expression was examined in isolated
astrocytic and microglial cell cultures. Cytokine and chemokine production was measured in IL-17A
treated cultures to evaluate the functional status of IL-17RA.
Results: Here we report increased IL-17RA expression in the CNS of mice with EAE, and constitutive
expression of functional IL-17RA in mouse CNS tissue. Specifically, astrocytes and microglia express IL-
17RA in vitro, and IL-17A treatment induces biological responses in these cells, including significant
upregulation of MCP-1, MCP-5, MIP-2 and KC chemokine secretion. Exogenous IL-17A does not
significantly alter the expression of IL-17RA in glial cells, suggesting that upregulation of chemokines by
glial cells is due to IL-17A signaling through constitutively expressed IL-17RA.
Conclusion: IL-17RA expression is significantly increased in the CNS of mice with EAE compared to
healthy mice, suggesting that IL-17RA signaling in glial cells can play an important role in autoimmune
inflammation of the CNS and may be a potential pathway to target for therapeutic interventions.
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IL-17A was described more than a decade ago [1], but
became a major focus of research only recently, after a
novel IL-17A-producing Th cell lineage (Th17) was dis-
covered [2-6]. Th17 cells are generated in response to
polarizing cytokines including TGFβ, IL-6, IL-23, IL-1β
and TNF [7-10]. Like other inflammatory cytokines, IL-
17A has both protective and pathogenic roles. IL-17A is
important for host defense against infectious organisms
[11-14]. However, elevated IL-17A in several autoimmune
diseases including MS/EAE [15-17] contributes to disease
pathogenesis. Deficiency or neutralization of IL-17A in
EAE reduces disease susceptibility and clinical severity
[18]. IL-17A can induce the expression of a range of
inflammatory mediators, and thus modulates the activi-
ties of inflammatory cells [19,20] through production of
numerous cytokines and chemokines involved in inflam-
matory responses [21].
Infiltration of inflammatory cells and encephalitogenic T
cells in the CNS is the hallmark of EAE [22]. IL-17A expres-
sion is increased in lymphocytes derived from EAE mice,
and anti-IL-17A antibody treatment during the recovery
phase in a relapsing remitting EAE model delays the onset
and reduces incidence and severity of relapses [23,24]. In
MS patients, IL-17A mRNA and protein are increased in
both brain lesions and mononuclear cells isolated from
blood and cerebrospinal fluid [25,26]. Recently, it was
demonstrated that IL-17A produced by Th17 cells is detect-
able at the blood brain barrier (BBB) in MS lesions, and
that IL-17A can promote BBB disruption in vitro [27].
IL-17A functions through a distinct ligand-receptor signal-
ing system [28]. IL-17RA is a widely expressed receptor
that binds IL-17A with high affinity [29]. Leukocytes from
mice lacking IL-17RA fail to bind IL-17A, and antibodies
against IL-17RA inhibit the activity of IL-17A on human
epithelial cells, indicating that IL-17RA is critical for IL-
17A function [30]. Recently it has been demonstrated in
infectious models in which neutrophils are crucial for
host defense, that IL-17RA deficiency results in reduced
chemokine levels and reduced neutrophil numbers, and
increased susceptibility to infection [11,12]. IL-17RA sig-
naling is implicated in both innate and adaptive elements
of infectious and autoimmune diseases [15]; however, lit-
tle is known about its signaling in the CNS. One reason
may be that IL-17RA is expressed in the CNS at a very low
level. Expression of IL-17RA in the CNS of healthy human
subjects is undetectable by immunofluorescence but the
receptor was expressed in CNS endothelial cells within
heavily infiltrated MS lesions [27]. Given the important
role that IL-17A plays in autoimmune diseases of the CNS,
it is important to understand responses of CNS cells to IL-
17RA signaling. Here, we have investigated expression
and function of IL-17RA in healthy and inflamed mouse
CNS tissues both in vitro and in vivo.
We report here that mouse CNS tissues express IL-17RA and
the level of RNA expression increases in the CNS of mice
with EAE. We also demonstrate in vitro that astrocytes and
microglia in isolated culture express IL-17RA. The expres-
sion level of IL-17RA in microglia/macrophages is higher
compared to astrocytes. Treatment of astrocyte cultures
(devoid of microglia) and microglia cultures (devoid of
astrocytes) with exogenous recombinant mouse IL-17A
protein showed functional activation of IL-17RA signaling
as demonstrated by increased chemokine secretion.
Methods
Mice
Eight-week-old and time pregnant C57Bl/6 mice were
purchased from the Jackson Laboratory (Bar Harbor, ME).
All animal procedures and care were conducted in accord-
ance with approved ethical guidance under the auspices of
the Thomas Jefferson University Animal Care and Use
Committee. IL-17RA deficient mice on the C57Bl/6 back-
ground were used as negative control [12], and were
kindly provided by David Abraham (Thomas Jefferson
University, Philadelphia, USA) with permission from
Amgen (Seattle, Washington, USA).
Induction of EAE
Mice were injected subcutaneously with 100 μg myelin
oligodendroglial glycoprotein (MOG35–55) peptide
(MEVGWYRSPFSRVVHLYRNGK) in complete Freund's
adjuvant containing 4 mg/ml Mycobacterium tuberculosis
H37Ra (Difco, Michigan, USA) at two sites on the back.
200 ng pertussis toxin was given intraperitonially on day
0 and 2 post-immunization (p.i.). Mice were scored daily
according to a 0–5 scale as follows: partial limp tail, 0.5;
full limp tail, 1; limp tail and waddling gait, 1.5; paralysis
of one hind limb, 2; paralysis of one hind limb and partial
paralysis of the other hind limb, 2.5; paralysis of both
hind limbs, 3; ascending paralysis, 3.5, = weakness of the
upper limb, 4; moribund, 4.5; death, 5 [31]. At 20 days
p.i. (peak of disease; average score 3) tissues were col-
lected for mRNA extraction and histology.
Histology
Mice were perfused transcardially with 40 ml of PBS fol-
lowed by PBS containing 4% paraformaldehyde (PFA).
Spleen, brain and spinal cord tissues were collected, post-
fixed in 4% PFA overnight at room temperature (RT) and
embedded in paraffin. 5 μm sections were processed and
stained with Hematoxylin and eosin (H&E) for assess-
ment of inflammation and Luxol Fast Blue (LFB) for
demyelination. Sections were assessed as follows [31];
Inflammation: 0, none; 1, a few inflammatory cells; 2,
organization of perivascular infiltrates; and 3, increasing
severity of perivascular cuffing with extension into the
adjacent tissue; Demyelination: 0, none; 1, rare foci; 2, a
few areas of demyelination; 3, large (confluent) areas of
demyelination.Page 2 of 12
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Immunohistochemical staining was performed on mouse
spleen, brain and spinal cord tissue sections by the avidin-
biotin-immunoperoxidase technique as per manufac-
turer's instruction (Vector Laboratories, Burlington, Cali-
fornia, USA) using biotinylated anti-mouse IL-17R
antibody (R &D Systems, Inc.) directed against the IL-
17RA extracellular domain and 3, 3' diaminobenzidine as
substrate.
Isolation of neonatal glial cell populations
Primary cultures of mixed glial cells from day 0 newborn
mice were prepared as described previously [32]. Briefly,
following the removal of meninges, brain tissues were
minced with a Pasteur pipette and passed through 100 μm
nylon mesh followed by a wash and centrifugation (300 ×
g for 10 min). The pellet was resuspended with a Pasteur
pipette, passed through a 70 μm nylon mesh, followed by
a second wash and centrifugation (300 × g for 10 min).
Following dilutions with feeder medium {Dulbeco's
essential medium (DMEM) containing 1% penicillin-
streptomycin, 0.2 mM L-glutamine and 10% fetal calf
serum (FCS)}, cells were plated and grown in a humidi-
fied incubator at 37°C. Cells were cultured until day 10,
with a medium change on day 4, then every 2–3 days. To
culture astrocytes free from microglia and to obtain pure
microglial cultures, feeding of mixed glial cultures was
stopped for the following 12–14 days. Cultures were then
rigorously agitated for 30–40 min in an orbital incubator
shaker at 200 rpm at 37°C to detach cells adhering to the
astrocyte monolayer. Thereafter, cells suspended in the
medium were collected and plated (8 × 105 cells/ml; 1.5
ml per chamber slide (Nunc, Rochester, New York, USA).
After 15 min, non-adherent cells were discarded and
adherent cells were maintained. Following this procedure,
cells were 98–99% positive for CD11b (microglia/macro-
phage marker) and were negative for glial fibrillary acidic
protein (GFAP), indicating a very high enrichment in
microglia. Microglia were maintained in DMEM with 10%
FCS, 1% Penicillin/Streptomycin and 1% L-glutamine.
Adherent astrocyte monolayers from the original culture
were trypsinized and resuspended in astrocyte specific
medium at 8 × 105 cells/ml; and 2 ml were plated on each
well of 6 well culture plates. Sub-cultured astrocytes were
85% positive for glial fibrillary acidic protein (GFAP) by
immunofluorescence and 60–80% by flow cytometry. In
a separate procedure, oligodendrocytes were isolated and
enriched from neonatal mouse brain tissue as described
earlier [33], producing cultures with 30–40% oli-
godendrocytes mixed with astrocytes.
Immunofluorescence
Cells were processed by double label immunofluores-
cence for recognition of microglia and astrocytes. CD11b
was used as microglia/macrophage surface marker; GFAP
as an intracellular astrocytic marker; A2B5 as an oli-
godendrocyte precursor marker; and Galc as a mature oli-
godendrocyte marker. Unfixed cells were incubated with
biotinylated anti-CD11b primary antibody for 30 min at
RT followed by Cy3 conjugated streptavidin secondary
antibody for 30 min. Cultures were then rinsed with
Ham's F12, fixed in 95% ethanol 5% acetic acid (vol/vol)
at -20°C for 10 min and washed in Ham's F12 (Invitro-
gen). For GFAP staining, cells were washed 3 times with
PBS, followed by PBS with 0.5% Triton X-100 and PBS
with 0.5% Triton X-100 and 2% heat-inactivated goat
serum. Cells were incubated with polyclonal GFAP antis-
era (DAKO, Carpinteria, California, USA) for 30 min,
washed, and labeled with Cy2-conjugated goat anti-rabbit
IgG. Cells were then washed, mounted into Mowiol, and
visualized by fluorescence microscopy (Olympus I X-80)
with a 20 PlanApo oil immersion objective (1.0 numerical
aperture). Images were acquired with a SensiCamQE High
Performance CCD Camera.
For the detection of IL-17RA protein expression on the cell
surface of isolated astrocytes and microglia, unfixed cells
were incubated with anti-IL-17R (S-18. sc-1902; Santa
Cruz Biotechnology, Inc. Santa Cruz, California, USA) pri-
mary antibody for 30 min at RT followed by Cy2-conju-
gated Hamster anti-goat IgG secondary antibody for 30
min. Cultures were then rinsed with Ham's F12, fixed in
2% PFA for 10 min and washed in Ham's F12, mounted
and visualized by fluorescent microscopy as mentioned
above. Double label immunofluorescence was performed
by using anti- GFAP mouse monoclonal antibody raised
in mouse in combination with anti-IL-17R raised in rab-
bit. For microglia cultures we used biotinylated anti-
CD11b primary antibody in combination with Cy3 con-
jugated streptavidin secondary antibody and anti-IL-17R.
Flow cytometry
Glial cell cultures were harvested and washed in buffer
containing 1% FCS, 0.1% NaN3 in PBS, and stained with
an APC-conjugated antibody to CD11b for 20 min in the
dark at 4°C. Cells were washed, fixed and permeabilized
using Fix and Perm® cell permebilization reagents (Caltag
Laboratories, Burlingame, CA). Cells were then stained for
intracellular GFAP with polyclonal anti-GFAP antibody
and PE-conjugated goat anti-rabbit IgG. Polyclonal anti-
mouse IL-17R-Carboxyfluorescein (R&D Systems) was
used to quantitatively determine the density of IL-17R on
the cell surface by flow cytometry. Cells were FC-blocked
by treatment with 1 μg of mouse IgG/106 cells for 15 min
at RT prior to staining. Protein G-purified normal goat-
IgG conjugated with carboxyfluorescein (CSF) (R&D Sys-
tems) was used as isotype control for IL-17RA staining.
IL-17A treatment in vitro
Functional studies were performed either on confluent
microglia subcultures obtained after 24 hr, or astrocyte
subcultures obtained after 72 hr hrs of plating. On the dayPage 3 of 12
(page number not for citation purposes)
Journal of Neuroinflammation 2009, 6:14 http://www.jneuroinflammation.com/content/6/1/14of stimulation, media were removed and cells were
washed with PBS. Recombinant mouse IL-17A (10 ng/ml
or 1–100 ng/ml where indicated) was added to the
selected culture wells. Non-stimulated sister cultures were
used as controls throughout the studies. Culture superna-
tants were collected at 3, 6, 12, 24 and 48 hr time points.
Search light chemokine arrays
Levels of 29 analytes including cytokines, chemokines,
growth factors and matrix metalloproteinases (Table 1) in
supernatants of cultures either treated with IL-17A or non-
stimulated, were assayed using a SearchLight Multiplex
Sandwich ELISA according to the manufacturer's instruc-
tions.
Extraction of RNA and synthesis of cDNA
Tissue RNA and cellular RNA was extracted with RNeasy
Midi or Mini kits (Qiagen, Chatsworth, CA) respectively
according to the manufacturers' recommendations. The
purity of total RNA was assessed using a NanoDrop® ND-
100 spectrophotometer (NanoDrop Technologies, Wilm-
ington, DE). One μg of total RNA was used to synthesize
cDNA with high capacity cDNA archive kit (Applied Bio-
systems Inc., Foster, CA) according to the manufacturers'
instructions.
Real time PCR
Quantitative Real-Time (RT)-PCR was performed on the
ABI PRISM 7000 Sequence Detection System using Taq-
Man® Universal PCR Master Mix (Applied Biosystems)
and TaqMan® Gene Expression Assays primer/probe
(Applied Biosystems; Assay ID: Mm00434214_m1-from
exon boundary 1–2) according to the manufacturer's
specifications. Additional primer probe was also selected
from exon boundary 3–4 (Assay ID. Mm01183143_m1)
for amplification as this region is disrupted in IL-17RA
deficient mice. To generate a standard curve for quantifi-
cation of templates, cDNA constructs either from exon
boundary 1–2 or 3–4 were cloned into pGEM® T Easy vec-
tor (Promega, Madison, Wisconsin, USA) and verified by
double strand sequencing. Respective cDNA constructs
were serially diluted 7 times at a ratio of 1:10. Thus, the
dynamic range for each gene was from 12 to 12,000,000
copies. Samples were analyzed in triplicate and experi-
ments performed three times. Amplification data were
analyzed with ABI Prism Sequence Detection Software 2.1
(Applied Biosystems).
Statistics
2-tailed, Student's Welch corrected t tests (for parametric
data) were used for statistical analysis. Differences were
considered significant if * p < 0.05.
Results
IL-17RA is constitutively expressed in CNS tissues
IL-17RA is expressed in most tissues examined to date,
although little is known about its expression in the CNS.
To investigate if IL-17RA is expressed in normal CNS tis-
sues, we harvested brain, spinal cord and, as a positive
control, spleen, from 10-week-old C57BL/6 female mice.
RNA was extracted and cDNA synthesized for quantitative
RT-PCR. Pearson's correlation coefficient of the standard
curve generated from serially-diluted cDNA constructs of
pGEMT-IL-17RA exon boundary 1–2 was 0.99. IL-17RA
was expressed in both brain and spinal cord with slightly
higher levels detected in brain. Levels of IL-17RA mRNA
in normal CNS were approximately 5-fold lower than that
of normal spleen (Figure 1A). Spleen has previously been
shown to have the highest levels of IL-RA expression [29],
and CNS expression was found to be slightly higher than
heart, skeletal muscle, and testes, the tissues with the low-
est expression levels [29]. To reconfirm the expression of
IL-17RA in CNS, we constructed another standard curve
using a plasmid expressing the IL-17RA gene from exon
boundary 3 – 4, and used IL-17RA deficient mice (in
which IL-17RA gene is disrupted between exon boundary
4 – 11) [12] as a negative control. Pearson's correlation
coefficient of the standard curve generated from serially-
diluted cDNA constructs of pGEMT-IL-17RA exon bound-
ary 3–4 was 0.98. No detectable amplification was
observed in samples from IL-17RA deficient mice, while
IL-17RA mRNA was again detected in brain and spinal
cord of wild-type C57BL/6 mice (Figure 1B). These results
demonstrate that normal mouse CNS tissues constitu-
tively express IL-17RA.
Table 1: List of analytes including cytokines, chemokines, growth 
factor and matrix metalloproteinases measured by multiplex 
array
Cytokines Chemokines Growth Factor
GM-CSF KC TGFβ
IFN-γ MCP-1 Matrix
Metalloproteinases
IL-1α MCP-5
IL-1β MIP-1α
IL-2 MIP-1β
IL-4 MIP-2 MMP-2
IL-5 MIP-3β MMP-3
IL-6 RANTES MMP-9
IL-10
IL-12p40
IL-13
IL-17
IL-18
IL-23
IL-27
TNF-αPage 4 of 12
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Mounting evidence suggests that IL-17A causes pathology
in autoimmunity, but little is known about mechanisms
of IL-17RA signaling. To examine if CNS inflammation
alters IL-17RA expression locally, we utilized the EAE
model induced in C57BL/6 mice with MOG35–55. As
shown in Figure 2A, these mice developed the classical
clinical profile of EAE. Spinal cords were harvested at the
peak of disease (day 20) for histopathological studies and
RNA extraction. In agreement with clinical findings, we
observed inflammatory demyelinating lesions in EAE
mice (Figure 2D–G). Quantitative RT-PCR using a stand-
ard curve (expressing the gene from the exon boundary 1
– 2) demonstrated nearly 5-fold more IL-17RA expression
in EAE spinal cords than healthy controls (Figure 2H).
These results suggest that inflamed CNS may have height-
ened responsiveness to IL-17A.
In situ detection of IL-17RA protein
To investigate in vivo cell specific expression of IL-17RA at
the protein levels in healthy mouse spleen (positive con-
trols) and CNS tissue we performed immunohistochemis-
try. Immunohistochemical studies showed that in spleen
a subset of cells, more specifically matured splenocytes
surrounding the germinal center, express IL-17RA protein
(Figure 3A and 3B) and cells within the germinal center
showed very little, if any, staining. In CNS tissues, high
background staining with 3, 3' diaminobenzidine made
interpretation difficult and unreliable (Figure 4). We have
performed western blot from the tissue lysates of spleen,
IL-17RA expression in mouse CNSFigure 1
IL-17RA expression in mouse CNS. Spleen, brain and 
spinal cord were harvested from 10-week-old C57BL/6 and 
IL-17RA-deficient mice and used for quantification of IL-
17RA mRNA by RT-PCR. Absolute copy number (mRNA 
molecules/μg total RNA) is shown. (A) Quantification of IL-
17RA mRNA in wild-type mice using a primer set from exon 
boundary 1–2. IL-17RA expression was detected in all sam-
ples with > 5-fold more expression in spleen than CNS. One 
experiment of three is shown. (B) Expression of IL-17RA 
assessed by RT-PCR using a primer set from exon boundary 3–4. 
IL-17RA expression was again observed in wild-type (WT) 
CNS, but not in IL-17RA-deficient mice. Mean and SEM gen-
erated from multiple animals in one experiment (of three) is 
shown.
IL-17RA expression in the CNS of EAE miceFigure 2
IL-17RA expression in the CNS of EAE mice. (A) Clini-
cal profile of EAE. Female C57BL/6 mice (n = 8) were immu-
nized with MOG35–55 and scored daily. Data represent mean 
clinical scores ± SEM. One experiment of three is shown. (B-
G). CNS inflammation and demyelination. Mice were sacrificed 
at day 20 p.i., spinal cords were harvested and 5 μm sections 
were stained with H&E (B, D, F) or LFB (myelin stain; C, E, 
G). Magnifications are 40× (B-E) and 100× (F, G). EAE mice 
had significant cellular infiltration (arrows; D, F) and demyeli-
nation (arrows; E, G). No inflammation or demyelination 
occurred in control mice (B, C). (H) IL-17RA expression is up-
regulated in the inflamed CNS of EAE mice. EAE and control 
mice (n = 5) were sacrificed at day 20 p.i. and IL-17RA 
expression from isolated spinal cords was assessed by RT-
PCR using a primer set from exon boundary 1–2. Expression 
of IL-17RA in EAE mice is upregulated > 5-fold (*** P < 
0.0001).Page 5 of 12
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antibody from R & D. None of the antibody was compat-
ible for mouse tissue lysates. Because in vivo CNS cell-spe-
cific detection of IL-17RA in healthy or EAE mice was
uninterpretable, in vitro cultures of specific CNS cell types
were used to further examine IL-17RA expression.
Glial cells express IL-17RA
To determine whether distinct CNS cell types express IL-
17RA, we used in vitro cell cultures. This averted technical
difficulties of high background staining levels in vivo in
the CNS, and also importantly eliminated the influence of
infiltrating peripheral immune cells that occurs in EAE.
We specifically examined glial cell cultures because astro-
cytes and microglia play significant roles in the develop-
ment of both innate and adaptive immune responses in
the CNS [34]. Using day 0 neonatal CNS tissue we first
established mixed glial cultures containing both astro-
cytes and microglia (Figure 5A). Enriched sub-cultures
were then established with astrocytes free of microglia, or
microglia free of astrocytes (Figure 5B and 5C respec-
tively). We verified isolated culture purities by flow
cytometry (Figure 5D–F) and found that microglial cul-
tures were 98–99% pure. Astrocyte cultures were 60–80%
GFAP-positive by flow cytometry, more than 85% pure by
immunofluorescence, and devoid of CD11b positive cells.
RNA was extracted from glial cultures (mixed glia, micro-
glia or astrocytes); cDNA was synthesized and analyzed by
RT-PCR using probes from exon boundary 1–2. IL-17RA
was expressed in all glial culture systems with highest
expression in microglial cultures (Figure 5G). For compar-
ison, IL-17RA expression was measured by RT-PCR in cul-
tures enriched for oligodendrocytes and was almost 50%
lower than in purified astrocytic cultures (data not
shown), likely reflecting the presence of 60% astrocytes in
these enriched cultured.
To determine whether neonatal glial cells in culture also
express IL-17RA at the protein level we labeled purified
astrocytes and microglia with commercially available
anti-IL-17R antibody raised against a peptide mapping at
the N-terminus of IL-17RA. We observed a significant
amount of punctuate staining for IL-17RA at the cell sur-
face of astrocytes (Figure 6A) whereas, in microglia, IL-
17RA staining was much weaker (Figure 6B). To quantita-
tively determine the expression of IL-17RA protein on our
neonatal purified astrocytes and microglia we stained the
cells with polyclonal anti-mouse IL-17R-fluorescent anti-
body which was designed to determine the density of
IL17RA on cell surface by flow cytometry. Protein G-puri-
fied normal carboxy fluorescent -conjugated goat IgG was
used as isotype control. Flow cytometric analysis of IL-
17RA- fluorescent antibody staining demonstrated that
16.8 ± 5.15% of GFAP positive cells were positive for IL-
17RA (Figure 6C) expression where as only 0.80 ± 0.42%
of cells were positive for IL-17RA in the purified micro-
glial population (Figure 6D). Both immunofluorescence
data and flow cytometric data are in agreement that glial
cells express IL-17RA at the protein level and among the
glial cells astrocytes express far more IL-17RA than micro-
glia.
Expression of IL-17RA protein in spleen tissue from adult mouseFigure 3
Expression of IL-17RA protein in spleen tissue from adult mouse. 5 μm thick serial cross sections of adult mouse 
spleen were processed for immunohistochemisty and immunostained with anti-IL-17RA antibody (A, B) followed by hematox-
yline counterstaining. Immunostained sections demonstrated a subpopulation of IL-17RA positive cells (appear in brown). Orig-
inal magnification for A was 100× and B was 400×.Page 6 of 12
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To study the functional responsiveness of glial cells to IL-
17A without the complex influence of inflammatory net-
works present during pathogenesis, we treated glial cul-
tures with exogenous IL-17A. Using a multiplex array
system we examined secretion of 29 different analytes
including cytokines, chemokines, matrix metalloprotein-
ases and growth factors (Table 1) by glial cells cultured for
12 hr in the presence or absence of exogenous IL-17A (10
ng/ml). Microglia and astrocytes each constitutively
expressed several chemokines (MCP-1, MCP-5, MIP-2,
MIP-1α, MIP-3β, KC and RANTES) (data not shown). IL-
17A treatment significantly upregulated the expression of
MCP-1, MCP-5, MIP-2 and KC (Figure 7A–H), with MIP-
2 and KC near the lower limits of detection. MIP-1α, MIP-
3β and RANTES expression were not significantly affected
by IL-17A in either astrocyte or microglia cultures, and no
significant cytokine upregulation was observed either
(data not shown). While TGFβ and MMPs were constitu-
tively expressed by astrocytes and microglia, exogenous
IL-17A treatment did not significantly alter this expression
(data not shown). We also treated cells with IL-17A at a
concentration range of 1–100 ng/ml and examined the
secretion of analytes (Table 1) at various time points. We
observed maximal upregulation of chemokines when IL-
17A was used at 10 ng/ml at the 12 hr time point, with no
difference between 10 and 100 ng/ml IL-17A treatments
from 12 to 48 hr (data not shown).
Exogenous IL-17A does not alter IL-17RA expression in 
glial cultures
To ensure that changes in chemokine expression induced
by IL-17A were due to signaling through constitutively
expressed IL-17RA, as opposed to an increase of IL-17RA
expression, we evaluated the influence of IL-17A treat-
ment on IL-17RA expression in astrocytes and microglia.
IL-17A did not significantly alter the constitutive expres-
sion of IL-17RA mRNA (p > 0.05) (Figure 8). This infers
that upregulation of chemokines by glial cells was due to
exogenous IL-17A signaling through constitutively
expressed IL-17RA.
Discussion
Increasing evidence suggests that IL-17A and Th17 cells
play a major role in autoimmune inflammation, but there
are gaps in our understanding of IL-17RA signaling mech-
anisms. IL-17RA is expressed in most tissues examined to
date and activates many of the same signaling cascades as
innate cytokines such as TNFα and IL-1β [35,36]. Thus IL-
17A is considered an important bridging molecule
Expression of IL-17RA protein in brain, spinal cord and spleen tissue from adult mouseFigure 4
Expression of IL-17RA protein in brain, spinal cord and spleen tissue from adult mouse. 5 μm thick serial cross 
sections were processed for immunohistochemisty. Immunostaining with anti-IL-17RA antibody and counterstaining with 
hematoxyline demonstrated a subpopulation of IL-17RA positive cells in spleen cells as shown here and in Figure 3 (C, D; 
appear in brown). Immunostained section of brain surrounding the hippocampal region (A) and cross section of spinal cord (B) 
demonstrated non-specific binding of IL-17RA. Original magnification for A, B and C was 100× and D was 400×.Page 7 of 12
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[15,37]. Furthermore, emerging knowledge regarding IL-
17A/IL-17RA signaling in numerous tissues suggests a
broader role in health and disease beyond the immune
system. Given this importance of IL-17RA signaling, it is
of particular interest to understand the role of IL17RA sig-
naling in the CNS of mice with autoimmune inflamma-
tory disease.
In our present study we demonstrated that healthy mouse
CNS constitutively expresses IL-17RA. To investigate cell-
specific expression of IL-17RA in healthy mouse CNS in
vivo we performed immunofluorescence on brain, spinal
cord and spleen tissue sections. Spleen cells had detecta-
ble Il-17RA expression both at mRNA and protein levels.
While our detection of IL-17RA mRNA in whole CNS tis-
sues by RT-PCR suggests that IL-17RA is expressed, unfor-
tunately immunohistochemical staining in the CNS was
IL-17RA expression in astrocytes and microglia in vitroFigure 5
IL-17RA expression in astrocytes and microglia in vitro. (A-C) Phenotypic characterization of glial cells by immunofluores-
cence. Mixed glial cultures (A), and purified astrocytic (B) and microglial cultures (C) were established from neonatal C57BL/6 
mice. Cultures were stained with anti-GFAP antibody (astrocytic marker; green) and anti-CD11b (microglial marker; red) and 
counterstained with nuclear stain DAPI (blue). Mixed glial cultures primarily consist of astrocytes (70–80%) and microglia (5–
10%); whereas, purified astrocyte cultures consist of 80–90% GFAP-positive cells. Purified microglial cultures are 98–99% 
CD11b-positive. (D-F). Flow cytometry. Glial cells were immunostained for flow cytometric analysis. Mixed glial cultures (D) con-
tain both GFAP- and CD11b-positive cells. Astrocyte cultures were free from microglia (< 0.5%) (E) and microglial cultures 
free of astrocytes (< 0.5%) (F). (G) IL-17RA expression in vitro. mRNA was extracted from glial cultures and IL-17RA expression 
was quantified by RT-PCR using a primer set from exon boundary 1–2. Data represent the mean ± SEM expression of total IL-
17RA mRNA from isolated cultures from three different batches of donors. IL-17RA is expressed 4-fold higher in microglia 
compared to astrocytes (***p < 0.0001). Mixed glial culture confers more expression of IL-17RA mRNA in comparison to 
astrocyte cultures devoid of microglia (*p = 0.0329).Page 8 of 12
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antibodies, or perhaps due to the overall expression levels.
Indeed, in human studies, Kebir et al. also were unable to
detect IL-17RA expression in situ in healthy CNS [27].
They did demonstrate, however, that IL-17RA is expressed
on CNS endothelial cells in MS lesions.
We also observed that, in comparison to healthy mice, the
expression of IL-17RA is significantly increased in the CNS
of mice with EAE. This is of particular relevance to MS and
EAE as Th17 cells and IL-17A have been implicated in dis-
ease pathogenesis [3,5]. As the CNS in the EAE model con-
tains peripheral immune cells that have infiltrated during
the inflammatory process, it is likely that increased expres-
sion of IL-17RA is partly due to the abundance of these
cells, but increased IL-17RA expression may also be due to
increased expression in resident CNS cells. Our in vitro
results suggest that expression can occur in astrocytes and
microglia, although similar low level expression in neu-
rons has not been excluded. In either case, whether from
resident cells or infiltrating cells, increased IL-17RA
expression in the inflamed CNS suggests a heightened
responsiveness to IL-17A signaling. Indeed, we observed
significant constitutive expression of the IL-17RA mRNA
in both astrocytes and microglia in purified cultures, free
of peripheral immune cells. At the protein level we
observed that mainly astrocytes express IL-17RA, with
microglia expressing only very little. The differential
expression of mRNA and protein in microglia and astro-
cytes could be due to a combination of gene expression
regulatory mechanisms and differences in post transla-
tional control. An important question is whether this level
of expression has any functional significance, and our
functional studies in vitro suggest that it may.
Although produced primarily by T cells, IL-17A is known
to trigger a variety of target cells to secrete inflammatory
mediators, including chemokines, cytokines and cell sur-
face receptors [28]. We verified that IL-17RA expression
on glial cells is functional by treating these cultures with
exogenous IL-17A and examining the expression of a
range of targets serving as surrogate markers of IL-17RA
Detection of IL-17RA protein on the cell surface of neonatal glial cellsFigure 6
Detection of IL-17RA protein on the cell surface of neonatal glial cells. Purified astrocytes (A) and microglia (B) cul-
tured on chamber slides were fluorescently labeled with anti-IL-17RA antibody and CY2 -conjugated Hamster anti-goat IgG 
secondary antibody. The majority of astrocytes showed punctuate surface staining (A), whereas IL-17RA staining was much 
weaker in microglia (B). Binding of polyclonal-anti-mouse IL-17R-fluorescein on the surface of isolated astrocytes and microglia 
was tested using flow cytometric analysis. Cells were double labeled with anti-GFAP (intracellular marker for astrocytes) and 
IL-17RA antibody (C) or anti-CD11b (for microglia) and IL-17RA antibody (D). Protein G- coupled normal goat-IgG conjugated 
with carboxyfluorescein was used as isotype. Cells were gated either for GFAP or for CD11b, and IL-17RA expression on 
gated cells shown in single parameter FACS plot against the isotype staining demonstrates a prominent population of IL-17RA 
positive astrocytes, but only rare positive microglia.Page 9 of 12
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terial products or potent endogenous activators of inflam-
mation (such as TNF-α or IFN-gamma) so as not to
obscure the constitutive profile of IL-17RA expression and
function in glial cells. Our functional studies demonstrate
that IL-17A treatment significantly upregulated the
expression of MCP-1, MCP-5, MIP-2 and KC in both puri-
fied astrocyte and microglia cultures. This suggests that
expression in even a small subpopulation of cells as seen
in microglial cultures is sufficient to mediate a significant
functional response. Moreover, upregulation of chemok-
ines by glial cells was exclusively due to exogenous IL-17A
signaling through constitutively expressed IL-17RA, as
exogenous IL-17A treatment did not significantly alter the
expression level of IL-17RA mRNA in microglia or astro-
cyte cultures.
These results suggest IL-17A may exert some of its proin-
flammatory effect through direct interaction with its
receptor on glial cells to regulate expression of several
chemokines. Some of these chemokines are known to
play a role in amplifying the inflammatory reaction in
EAE/MS [38]. Moreover, the upregulation of these chem-
okines suggests that the low level of IL-17RA expressed on
astrocytes and microglia is functional, and may have bio-
logical significance in CNS inflammation. In mice with
EAE, IL-17A may be secreted from CD4+ T cells/Th17
infiltrating cells and bind to IL-17RA on CNS resident
glial cells, which in turn can secrete chemokines that
attract a range of other inflammatory cells, such as KC and
MIP-2 that are known to recruit neutrophils [39]. Moreo-
ver, glial cells may be part of the cellular machinery that
IL-17A uses in the CNS to steer local inflammation. Inter-
estingly, IL17 may lead to production of a different set of
inflammatory mediators in other cell types, as IL-17 bind-
ing to an IL-17 receptor expressed on epithelial, endothe-
lial, and fibroblastic stromal cells results in the secretion
of IL-1, TNF-alpha, IL-6, IL-8, or prostaglandin E2 [40].
Together with our results, this suggests that IL-17 binding
Exogenous IL-17A treatment induces chemokine secretion in vitroFigure 7
Exogenous IL-17A treatment induces chemokine 
secretion in vitro. (A-H) Isolated astrocyte and microglia 
cultures were treated with IL-17A (10 ng/ml). Culture super-
natants from treated and non-treated cultures were col-
lected at 12 hr and assessed for chemokine levels by a 
multiplex array system. In response to IL-17A, microglia and 
astrocytes each upregulated secretion of MCP-1, MCP-5, 
MIP-2 and KC. One experiment of three is shown. *p < 0.05, 
***p <0.0001. Mean ± SEM was generated from three multi-
ple wells of the single experiment.
Exogenous treatment of IL-17A does not alter IL-17RA e pr ssion in glial cultureFigure 8
Exogenous treatment of IL-17A does not alter IL-
17RA expression in glial culture. mRNA was isolated 
from either non-treated resting culture or IL-17A (10 ng/ml) 
treated culture supernatants at 12 hr in vitro. IL-17RA gene 
expression was measured by RT-PCR using a primer set 
from exon boundary 1–2. Data represent the mean expres-
sion from three different non- treated and IL-17A- treated 
culture batches ± SEM. IL-17A treatment did not alter IL-
17RA expression in neonatal glial cells (*p > 0.05).Page 10 of 12
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ther characterization in specific disease models.
Conclusion
Together, our studies demonstrate that both astrocytes
and microglia are responsive to IL-17A. However, full
functional stimulation by IL-17A may require additional
inflammatory signals (e.g. IFN-γ, TNF-α, IL-1β, LPS) not
present in our in vitro system. Indeed, the cellular
response elicited in glial cells by IL-17A will likely differ
depending on the inflammatory status of the tissue. In
addition, cross communication between IL-17A and
other cytokine signaling systems would likely modify the
response of glial cells to IL-17A. Infiltration of IL-17A-
secreting T cells has clearly been demonstrated to be a
pathogenic event in EAE. The resultant cellular and
chemokine milieu and its effect on IL-17RA signaling in
glial cells warrant detailed study in the future. Nonethe-
less, here we have demonstrated for the first time that IL-
17RA is expressed constitutively in mouse CNS, is upreg-
ulated during EAE, and is expressed on astrocytes and
microglia suggesting a role for glial IL-17A signaling in
mediating CNS inflammation.
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